EUVIMEDEUVIMED entdecken
FallberichtLeserbrief

Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL ‐23 inhibition

Connor Cole iD, Kyle T Amber

Journal of the European Academy of Dermatology and Venereology · 2023

DOI: 10.1111/jdv.19317 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Journal of the European Academy of Dermatology and Venereology, 2023. Verfasst von Connor Cole und 1 weiteren Autor:innen. Beteiligte Einrichtung: Rush Medical College, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Pemphigoid, Bullous, Psoriasis, Skin Diseases, Vesiculobullous. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 10 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pemphigoid, BullousPsoriasisSkin Diseases, VesiculobullousHumansInterleukin-23

Substanzen

Interleukin-23

Autor:innen und Institutionen

  • Rush Medical College, Chicago, Illinois, USA.
  • Department of Dermatology, Rush University Medical Center, Chicago, Illinois, USA.
  • Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.

ORCID-Profile: Connor Cole

Zitieren

APA

Cole, C., & Amber, K. T. (2023). Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL ‐23 inhibition. Journal of the European Academy of Dermatology and Venereology. https://doi.org/10.1111/jdv.19317

Vancouver

Cole C, Amber KT. Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL ‐23 inhibition. Journal of the European Academy of Dermatology and Venereology. 2023. doi:10.1111/jdv.19317

BibTeX
@article{Cole2023,
  author = {Cole, Connor and Amber, Kyle T},
  title = {Two patients with concomitant bullous pemphigoid and psoriasis successfully treated by IL ‐23 inhibition},
  journal = {Journal of the European Academy of Dermatology and Venereology},
  year = {2023},
  doi = {10.1111/jdv.19317}
}
Kostenlos starten →